In clinical trials, the antibodies of IL-23p19, IL-23p40, IL-17A, and IL-17RA have shown promising efficacy in the treatment of many autoimmune diseases including psoriasis, ankylosing spondylitis, and multiple sclerosis [26, 46]. Here, IL17A is linked to ankylosing spondylitis.